Recent news includes the appointment of a new CFO at Iron Horse Acquisitions Corp., the predecessor entity to CN Healthy Food Tech Group Corp., reported in October 2024.

• Iron Horse Acquisitions Corp. appointed a new Chief Financial Officer as reported on October 28, 2024 [N1].

The company’s focus on combining modern biotechnology with traditional Chinese medicine principles positions it to serve a niche market with growing consumer interest in health and wellness products. Its wholly-owned subsidiaries in China provide direct operational control and potential for product innovation. The company’s reported profitability and liquidity as of September 2025 indicate operational progress and financial stability. The recent appointment of a new CFO at Iron Horse Acquisitions Corp. may support improved financial management and strategic execution [N1].

The company faces significant regulatory risks due to the ongoing review by the China Securities Regulatory Commission, which has resulted in a trading halt on Nasdaq since October 2025. This trading suspension limits liquidity and may impair the company’s ability to raise capital or maintain investor confidence. The complex and evolving regulatory environment in China, including requirements for overseas listings and foreign investment restrictions, adds uncertainty to the company’s operations and financial condition. The company’s reliance on OEM suppliers introduces supply chain risks, and its limited operational history constrains visibility into sustainable growth and profitability. Potential delisting from Nasdaq could further reduce market access and shareholder value.

CN Healthy Food Tech Group Corp.’s moat is based on its integration of AI-powered biotechnology with traditional Chinese medicine to develop premium health food products, which addresses a growing market demand for safe, high-quality nutritional options in China. The company’s wholly-owned subsidiaries provide a localized operational base within China, potentially enabling closer alignment with regulatory requirements and market preferences. However, the company’s reliance on OEM suppliers for manufacturing and its relatively recent operational history limit its competitive advantages. Additionally, regulatory uncertainties and trading restrictions on Nasdaq pose challenges to its market presence and capital access, which may affect its ability to sustain and expand its moat.

• Nasdaq Trading Halt and Potential Delisting: Trading of the company’s securities on Nasdaq has been suspended since October 1, 2025, due to incomplete regulatory review by the China Securities Regulatory Commission. Prolonged suspension or delisting could materially reduce liquidity, market quotations, and the company’s ability to raise capital, and may lead to shareholder lawsuits [S1, S2].
• Regulatory Approval Uncertainty in China: The company must complete filings and obtain approvals from the China Securities Regulatory Commission for its overseas listing and business combination. Delays or failure to obtain such approvals could result in fines, penalties, operational restrictions, and adverse impacts on business and financial condition [S1].
• Operational Risks in China: The company’s operations are subject to complex and evolving Chinese laws and regulations, including cybersecurity, data privacy, and foreign investment controls. Non-compliance or regulatory changes may adversely affect operations and securities value [S1].
• Supply Chain Dependence: The company relies entirely on OEM suppliers for raw materials and manufacturing, exposing it to risks of production delays, shortages, and quality control issues that could impact product availability and customer satisfaction [S1].
• Limited Operational History: The company commenced operations in May 2024 and has limited historical data to assess its ability to meet market demand, expand capacity, and sustain profitability, which introduces uncertainty in business planning and execution [S1].
• Cross-Border Cash Transfer Restrictions: Most cash and equivalents are held by PRC subsidiaries, and regulatory restrictions on transferring funds out of China may limit the company’s ability to pay dividends or fund operations outside China [S1, S2].

• CN Healthy Food Tech Group Corp. is a holding company with no substantive operations; its core business is managed by domestic wholly-owned subsidiaries in China focused on developing, manufacturing, and marketing premium health foods driven by AI-powered biotechnology and biotech innovation integrating modern biotechnology with traditional Chinese medicine principles [S1].
• The company’s subsidiaries include Heilongjiang Zhongnengliangke Agricultural Technology Co., Ltd., Harbin Kangliang Kechuang Co., Ltd., Heilongjiang Beikang Biotechnology Co., Ltd., Harbin Nongke Internet Technology Co., Ltd., and Zhuhai Liangke Biotechnology Co., Ltd. [S1].
• The company completed a business combination with Iron Horse Acquisition Corp. on September 30, 2025, and began trading on Nasdaq under ticker UCFI on October 1, 2025 [S1].
• Trading of the company’s common stock and warrants on Nasdaq has been halted since October 1, 2025, due to the China Securities Regulatory Commission (CSRC) not completing its review of the company’s U.S. listing; the company has provided additional documentation and legal opinions but the halt remains in effect [S1, S2].
• The company’s business operations are primarily conducted in China and are subject to complex and evolving Chinese laws and regulations, including regulatory approvals for overseas issuances and cybersecurity and data privacy regulations, which may affect its ability to issue securities or operate [S1].
• The company’s financial snapshot as of September 30, 2025, shows cash and equivalents of approximately $37.2 million, current assets of $46.2 million, current liabilities of $38.2 million, a current ratio of 1.21, and a cash ratio of 0.97 [S2].
• For the three months ended September 30, 2025, the company reported revenue of approximately $7.9 million, net income of approximately $3.3 million, and basic and diluted EPS of $0.07 per share [S2].
• The company’s operations commenced in May 2024, with key products including grain-based health foods such as Shangshan Suyang Porridge, plant-based essential oils, collagen peptide prebiotics, natto compound gummy supplements, and similar products [S1].
• The company relies on OEM suppliers for sourcing raw materials and manufacturing finished products, exposing it to supplier disruption risks [S1].
• The company’s marketing strategy includes digital and offline channels, social media, influencer campaigns, and advertising to attract and retain distributors and customers [S1].
• The company faces significant risks related to the Nasdaq trading halt, including limited liquidity, potential delisting, reduced ability to raise capital, and possible shareholder lawsuits [S1, S2].
• The company must comply with Chinese government regulations on overseas listings, including filing with the CSRC, which remains incomplete as of the latest filings, creating regulatory uncertainty [S1].
• The company’s subsidiaries are required to participate in government-mandated employee benefit plans and comply with PRC labor and regulatory requirements [S2].
• The company’s cash and cash equivalents are held by its PRC subsidiaries, and cross-border cash transfers are subject to PRC regulatory restrictions, which may limit dividend payments and capital movements [S1, S2].
• The company’s financials show operating cash flow used of $1.67 million for the six months ended June 30, 2025, with cash and equivalents of $40.2 million as of that date [S2].
• Recent news includes the appointment of a new CFO at Iron Horse Acquisitions Corp., the predecessor entity, reported on October 28, 2024 [N1].